- An obscure sliver of RNA with a grim-sounding name is unexpectedly taking center stage as a linchpin in transforming pre-leukemic cells into full-blown leukemia, US-based Apexian Pharmaceuticals said.
Apexian Pharmaceuticals' latest studies in collaboration with Indiana University's Simon Cancer Center investigator Dr.
Kapur's and Apexian's results also support others' findings that Morrbid controls myeloid cell lifespan.
Kapur and Apexian's chief science officer, Mark Kelley, PhD demonstrated that Apexian's flagship compound APX3330 could reduce Morrbid's activity.
Apexian pharmaceuticals is taking a different approach in developing a drug that binds to APE1/Ref-1, a dual protein that is crucial in the development and growth of tumors in pancreatic cancer and is particularly dependent on APE1/Ref-1 .
Vinluan, Led by Former Lilly Exec, Apexian Out to Tackle Pancreatic Cancer, Xconomy, November 2016, http://www.xconomy.com/indiana/ 2016/11/16/led-by-former-lilly-execapexian-out-to-tackle-pancreatic-cancer/ ?singlepage=true.
- Indianapolis, Indiana-based cancer therapeutics developer Apexian Pharmaceuticals has opened a clinical trial for patients with advanced solid tumors, the company said.
Data indicates that Apexian's drug APX3330 inhibits the cancer-promoting activity of APE1/Ref-1 without causing the side effects normally associated with many types of chemotherapy.
Apexian Pharmaceuticals is a clinical-stage biotechnology company focused on developing safe and effective therapy for patients with high unmet medical needs.
- Indianapolis, Indiana-based cancer therapeutics developer Apexian Pharmaceuticals is closing its series A financing round, the company said.
Apexian has developed robust non-clinical data demonstrating APX3330 prevents and/or reverses such damage and is the basis for pursuing an indication for chemotherapy induced peripheral neuropathy.